''United we stand divided we fall.''-Alexandre Dumas, The Three Musketeers.
Multiple system atrophy (MSA) is a rare neurodegenerative disease that affects both men and women and has no clear ethnic or racial susceptibilities. Cases are geographically spread throughout the world. Age of onset is typically in the mid-50s. Based on MSA prevalence rates [6] and 32 % of Americans being over 50, estimates suggest there are around 5200 Americans suffering from MSA. The rarity of the disease in combination with the geographical spread of the cases is the biggest hurdle when it comes to enrolling patients in clinical trials. It is thought that with so few cases, no single treatment center-and probably no single country-has enough patients to perform well-powered translational research.
MSA is considered an orphan disease-because it affects less than 200,000 Americans. Orphan diseases are surprisingly common, with an estimated 7000 different orphan diseases affecting around 30 million Americans. Awareness of these rare diseases is growing fast. The National Institutes of Health (NIH) released a position paper recommending that each rare disease should have a dedicated global registry and data repository. They emphasized the importance of collecting de-identified clinical data in a standardized fashion overtime and having this information linked to tissue samples stored in bio-specimen banks [2] .
Gathering specific information from a large pool of patients has obvious advantages when it comes to defining true rates of disease progression as well as the impact of common treatment interventions. Well-defined patient cohorts also lay the foundation for future biomarker research. This strength in numbers approach requires an international collaborative effort that brings together clinical centers conducting research on MSA. Fortunately, in the case of MSA, these collaborative consortia working on the disease already exist.
MSA is a central focus of the North American Autonomic Disorders Consortium, created in 2009, as part of the Rare Diseases Clinical Research Network (RDCRN)-a partnership between several NIH Programs [3]. The Consortium (http://www.Rarediseasesnetwork.org/ARDCRC) has an ongoing prospective natural history study of MSA, and recently completed a controlled trial to test the neuroprotective potential of the old antibiotic rifampicin. Although the trial ultimately proved negative, the undertaking showed that it was possible to enroll 100 early MSA patients in little under a year [4] .
The European counterpart is the European MSA Study Group (EMSA-SG), founded in 1999, from sites in Austria, Denmark, France, Germany, Italy, Portugal, Sweden, Spain, and Great Britain. The European MSA Study Group (http://www.emsa-sg.org) published a report of its prospective MSA cohort that had been followed for 2 years [5] , which defines much of what we know about the motor progression rates in MSA. They have also completed several clinical trials.
In 2013, the MSA Coalition (http://www.multi plesystematrophy.org), a patient and caregiver advocacy group, provided support for an initiative to form a transatlantic alliance that would unite North American and European MSA Centers. The organization and structure are now in place and a standardized dataset has been agreed upon. Sites in Europe, the United States, and South America have signed agreements to contribute the standardized data set that will be used to follow the motor and autonomic features of MSA overtime (Fig. 1) .
On a day-to-day basis, natural history studies are challenging and require endless hours pouring through case report forms and entering data, but the efforts pay off in the long term. Large and well thought out natural history studies can provide valuable information for drug development. They are the only way to understand the variability in disease severity amongst patients and to reliably estimate the sample size necessary to sufficiently power a study with a clinically meaningful endpoint [1] . Natural history studies also help to define rates of progression of affected patients outside of a clinical trial. By describing the natural course of the disease, an international prospective study of MSA should also help to define guidelines for clinical care.
The argument for an international registry and natural history study is convincing. Sharing data across academic institutions and international boundary lines requires understanding of local rules and regulations, but it is possible. The continued support of the MSA Coalition and the NIH Rare Diseases Clinical Research Network will make the project feasible. 
